Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO

NEXT STORY
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference
PREV STORY
New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

author_avatar
NASDAQ Market News

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

author_avatar
NASDAQ Market News

Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

author_avatar
NASDAQ Market News